BRCA1 and breast carcinoma: A few years later, in 2018, olaparib became the first PARP inhibitor approved by the FDA for the second-line treatment of breast cancer patients with BRCA1/2 germline mutations who have previously undergone chemotherapy or hormone therapy if hormone receptor-positive [241].